Clinico-pathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: Analysis of 318 microdissected thyroid lesions

Endocrine-Related Cancer

Volumn 11, Issue 2, 2004, Pages 365-376

  Trovato, Maria ^a   Ulivieri, Alessandra ^b   Dominici, Roberto ^c   Ruggeri, Rosaria Maddalena ^a   Vitarelli, Enrica ^a   Benvenga, Salvatore ^a   Barresi, Gaetano ^a   Trimarchi, Francesco ^a   Brunetti, Ercole ^b   Vecchione, Aldo ^d   Andreoli, Mario ^d   Sciacchitano, Salvatore ^b,d,e  

^a UNIVERSITY OF MESSINA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c CNR   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CELL POPULATION; CELL TYPE; CHROMOSOME 7Q; CHROMOSOME ANALYSIS; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENE MAPPING; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALIGNANT TRANSFORMATION; MICROSATELLITE MARKER; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID HYPERPLASIA; THYROID NODULE; TUMOR GROWTH;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 7; HUMANS; HYPERPLASIA; LASERS; LOSS OF HETEROZYGOSITY; MICRODISSECTION; MICROSATELLITE REPEATS; MIDDLE AGED; THYROID GLAND; THYROID NEOPLASMS;

EID: 3042547289     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110365     Document Type: Article

References (38)

1. Baloch ZW & LiVolsi AV 2002 Follicular-patterned lesions of the thyroid. The bane of the pathologist American Journal of Clinical Pathology 117 143-150.
2. Baloch ZW, Fleisher S, LiVolsi AV & Gupta PK 2001 Diagnosis of follicular neoplasm, a gray zone in thyroid fine-needle aspiration cytology. Diagnostic Cytopathology 16 41-44.
3. Brander A, Viikinkoski P, Tuuhea J, Voutilainen L & Kivisaari L 1992 Clinical versus ultrasound examination of the thyroid gland in common clinical practice. Journal of Clinical Ultrasound 20 37-42.
4. Califano JA, Johns MM III, Westra WH, Lango MN, Eisele D, Saji M, Zeiger MA, Udelsman R, Koch WM & Sidransky D 1996 An allelotype of papillary thyroid cancer. International Journal of Cancer 69 442-444.
5. Dhillon VS, Husain SA & Ray GN 2003 Expression of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer, ovarian cancer, and non-small-cell lung cancer patients. Teratogenesis, Carcinogenesis and Mutagenesis (Suppl) 1 35-45.
6. Fagin JA 1992 Molecular defects in thyroid gland neoplasia. Journal of Clinical Endocrinology and Metabolism 75 1398-1400.
7. Fagin JA 2002 Mini review: Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Molecular Endocrinology 16 903-911.
8. Fonseca E & Sabrinho-Simoes M 1995 Diagnostic problems in differentiated carcinoma of the thyroid. Pathology Research and Practice 191 318-331.
9. Glick A, Popescu N, Alexander V, Ueno H, Bottinger E & Yuspa SH 1999 Defects in transforming growth factor beta signaling cooperate with a Ras oncogene to cause rapid aneuploidy and malignant transformation of mouse keratinocytes. PNAS 96 14949-14954.
10. Grebe SK, McIver B, Hay ID, Wu PS, Maciel LM, Drabkin HA, Goellner JR, Grant CS, Jenkins RB & Eberhardt NL 1997 Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 82 3684-3691.
11. Han SY, Druck T & Huebner K 2003 Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics 81 105-107.
12. Hay ID, Reading CC & Charbonau JW 1984 High-resolution real-time ultrasonography and unsuspected micronodular thyroid disease [letter] Lancet I 916.
13. Huang H, Reed CP, Mordi A, Lomberk G, Wang L, Shridhar V, Hartmann L, Jenkins R & Smith DI 1999 Frequent deletions within FRA7G at 7q312 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 24 48-55.
14. Kitamura Y, Shimizu K, Tanaka S, Ito K & Emi M 2000 Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clinical Cancer Research 6 1819-1825.
15. Kitamura Y, Shimizu K, Ito K, Tanaka S & Emi M 2001 Allelotyping of follicular thyroid carcinoma frequent allelic losses in chromosome arms 7q, 11p, and 22q. Journal of Clinical Endocrinology and Metabolism 86 4268-4272.
16. Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, Sigurdardottir S, Barnard J, Hallbeck B, Masson G, Shlien A, Palsson ST, Frigge ML, Thorgeirsson TE, Gulcher JR & Stefansson K 2002 A high-resolution recombination map of the human genome. Nature Genetics 31 241-247.
17. Kubo K, Yoshimoto K, Yokogoshi Y, Tsuyuguchi M & Saito S 1991 Loss of heterozygosity on chromosome 1p in thyroid adenoma and medullary carcinoma, but not in papillary carcinoma. Japanese Journal of Cancer Research 82 1097-1103.
18. LiVolsi AV 1990 Follicular Lesions of the Thyroid. In Surgical Pathology of Thyroid, Ch 9, pp 173-203. Philadelphia PA: Saunders.
19. Matsuo K, Tang SH & Fagin JA 1991 Allelotype of human thyroid tumors loss of chromosome 11q13 sequences in follicular neoplasm. Molecular Endocrinology 5 1873-1879.
20. Mortensen JD, Woolner LB & Bennet WA 1955 Gross and microscopic findings in clinically normal thyroid glands. Journal of Clinical Endocrinology 15 1270-1276.
21. Oller AR, Rastogi P, Morgenthaler S & Thilly WG 1989 A statistical model to estimate variance in long term-low dose mutation assays-testing of the model in a human lymphoblastoid mutation assay. Mutation Research 216 149-161.
22. Oriola J, Halperin I, Mallofre C, Muntane J, Angel M & Rivera-Fillat F 2001 Screening of selected genomic areas potentially involved in thyroid neoplasm. European Journal of Cancer 37 2470-2474.
23. Rosai J, Carcangiu ML & De Lellis R 1992a in Tumors of the Thyroid Gland, Atlas of Tumor Pathology, Third series, Fascicle 5: Classification of thyroid tumors, pp 19-20. Washington, DC: Armed Forces Institute of Pathology.
24. Rosai J, Carcangiu ML & De Lellis R 1992b in Tumors of the Thyroid Gland, Atlas of Tumor Pathology, Third series, Fascicle 5: Thyroid tumors. General considerations, pp 327-335. Washington, DC: Armed Forces Institute of Pathology.
25. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ & Fagin JA 2000 The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19 3948-3954.
26. Segev DL, Saji M, Phillips GS, Westra WH, Takiyama Y, Piantadosi S, Smallridge RC, Nishiyama RH, Udelsman R & Zeiger MA 1998 Polymerase chain reaction-based microsatellite polymorphism analysis of follicular and Hurthle cell neoplasms of the thyroid. Journal of Clinical Endocrinology and Metabolism 83 2036-2042.
27. Studer H 1988 Thyroid growth in vivo. In Progress in Endocrinology, vol. 2, pp 1053-1061. Eds H Imura, K Shizume & S Yoshida. Amsterdam: Excerpta Medica.
28. Studer H & Derwahl 1995 Mechanisms of non neoplastic endocrine hyperplasia - a changing concept. A review focused on the thyroid gland. Endocrine Reviews 16 411-426.
29. Sutherland GR, Baker E & Richards RI 1998 Fragile sites still breaking. Trends in Genetics 14 501-506.
30. Thiagalingam S, Foy RL, Cheng K, Lee HJ, Thiagalingam A & Ponte JF 2002 Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer-molecular basis of its occurrence. Current Opinion in Oncology 14 65-72.
31. Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF & Heffess HCS 2001 A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 91 505-524.
32. Trovato M, Fraggetta F, Villari D, Batolo D, Mackey K, Trimarchi F & Benvenga S 1999 Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 84 3235-3240.
33. Tung WS, Shevlin DW, Kaleem Z, Tribune DJ, Wells Jr SA & Goodfellow PJ 1997 Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer 19 43-51.
34. Ward LS, Brenta G, Medvedovic M & Fagin JA 1998 Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. Journal of Clinical Endocrinology and Metabolism 83 525-530.
35. Yunis JJ & Soreng AL 1984 Constitutive fragile sites and cancer. Science 226 1199-1204.
36. Zedenius J, Wallin G, Svensson A, Grimelius L, Hoog A, Lundell G, Backdahl M & Larsson C 1995 Allelotyping of follicular thyroid tumors. Human Genetics 96 27-32.
37. Zenklusen JC, Hodges LC, LaCava M, Green ED & Conti CJ 2000 Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site. Oncogene 19 1729-1733.
38. Zhang JS, Nelson M, McIver B, Hay ID, Goellner JR, Grant CS, Eberhardt NL & Smith DI 1998 Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors. Oncogene 17 793-798.